Clinically available medicines demonstrating anti-toxoplasma activity

Andrew J. Neville, Sydney J. Zach, Xiaofang Wang, Joshua J. Larson, Abigail K. Judge, Lisa A. Davis, Jonathan L. Vennerstrom, Paul H. Davis

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations


Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.

Original languageEnglish (US)
Pages (from-to)7161-7169
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Issue number12
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Clinically available medicines demonstrating anti-toxoplasma activity'. Together they form a unique fingerprint.

Cite this